Toronto Dominion Bank’s Apellis Pharmaceuticals APLS Stock Holding History

Toronto Dominion Bank’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,236,436	Closed	-$49.7M	–	2298
2026 Q1	$49.7M	Buy	+1,236,436	New	+$26.6M	0.07%	239
2025 Q3	–	Sell	-23,437	Closed	-$406K	–	1929
2025 Q2	$406K	Sell	23,437 -138,753	-86%	-$2.57M	﹤0.01%	1209
2025 Q1	$3.55M	Sell	162,190 -834,863	-84%	-$23.1M	0.01%	780
2024 Q4	$31.8M	Buy	997,053 +971,431	+3,791%	+$29.2M	0.05%	254
2024 Q3	$739K	Buy	25,622 +1,022	+4%	+$37.8K	﹤0.01%	876
2024 Q2	$944K	Buy	24,600 +14,601	+146%	+$661K	﹤0.01%	898
2024 Q1	$588K	Buy	+9,999	New	+$637K	﹤0.01%	932
2023 Q3	–	Sell	-119	Closed	-$11K	–	1831
2023 Q2	$11K	Buy	+119	New	+$10.3K	﹤0.01%	1282
2022 Q1	–	Sell	-38,421	Closed	-$1.82M	–	1410
2021 Q4	$1.82M	Buy	+38,421	New	+$1.51M	﹤0.01%	867

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Toronto Dominion Bank's APLS Position: Q2 2026 in Review

Toronto Dominion Bank sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,236,436 shares — an estimated $49.7M sold.

Toronto Dominion Bank first reported a position in APLS in Q4 2021 and held it in 9 quarters. The position peaked at $49.7M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Toronto Dominion Bank reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Toronto Dominion Bank sold 1,236,436 Apellis Pharmaceuticals shares in Q2 2026, an estimated $49.7M.
Toronto Dominion Bank first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Toronto Dominion Bank's Apellis Pharmaceuticals position peaked at $49.7M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Toronto Dominion Bank's 13F filing for Q2 2026, filed 14 Aug 2026.